Drugs: Side Effects
The question
To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the average time from initiating a dopamine agonist, or increasing its dose, to (a) the onset or first report of impulse control disorder symptoms and (b) formal recognition and recording of dopamine agonist-associated impulse control disorders; and how those intervals vary by indication, care setting and method of detection.
Answered by Preet Kaur Gill
The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.
Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.
The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.
The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →